Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ELUTNASDAQ:PASGNASDAQ:VTGNNASDAQ:ZURA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeELUTElutia$1.90+4.4%$2.08$1.61▼$5.24$78.12M0.8651,304 shs10,781 shsPASGPassage Bio$0.42-6.0%$0.36$0.26▼$1.33$26.28M1.71361,396 shs316,194 shsVTGNVistagen Therapeutics$2.36-0.4%$2.29$1.90▼$4.21$68.11M0.7171,679 shs83,745 shsZURAZura Bio$1.26+9.6%$1.20$0.97▼$5.07$86.15M-0.12427,980 shs995,668 shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceELUTElutia0.00%+5.56%-4.76%-31.65%-43.11%PASGPassage Bio0.00%-1.70%+21.98%-8.09%-66.44%VTGNVistagen Therapeutics0.00%-6.35%+4.89%-14.49%-39.49%ZURAZura Bio0.00%+24.14%-0.40%0.00%-72.37%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationELUTElutia3.3147 of 5 stars3.54.00.00.02.43.30.6PASGPassage Bio2.4131 of 5 stars3.53.00.00.00.61.71.3VTGNVistagen Therapeutics0.7648 of 5 stars0.03.00.00.00.61.71.3ZURAZura Bio2.4974 of 5 stars3.61.00.00.03.02.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceELUTElutia 3.00Buy$8.00321.05% UpsidePASGPassage Bio 3.00Buy$7.501,673.89% UpsideVTGNVistagen Therapeutics 4.00Strong BuyN/AN/AZURAZura Bio 3.13Buy$14.331,037.57% UpsideCurrent Analyst Ratings BreakdownLatest PASG, ZURA, ELUT, and VTGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/9/2025ELUTElutiaLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$10.00 ➝ $8.005/9/2025ZURAZura BioOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$19.00 ➝ $17.004/3/2025ZURAZura BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy4/3/2025ZURAZura BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$5.00 ➝ $3.003/26/2025ZURAZura BioOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$20.00 ➝ $19.003/26/2025ZURAZura BioGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.003/26/2025ZURAZura BioChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $10.00(Data available from 6/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookELUTElutia$23.71M3.29N/AN/A($1.66) per share-1.14PASGPassage BioN/AN/AN/AN/A$2.03 per shareN/AVTGNVistagen Therapeutics$698K97.58N/AN/A$2.81 per share0.84ZURAZura BioN/AN/AN/AN/A$1.85 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateELUTElutia-$37.66M-$1.93N/AN/AN/A-218.72%N/A-142.61%7/28/2025 (Estimated)PASGPassage Bio-$102.06M-$1.02N/AN/AN/AN/A-72.53%-52.10%8/6/2025 (Estimated)VTGNVistagen Therapeutics-$29.36M-$1.48N/AN/AN/A-6,777.08%-48.12%-43.80%6/10/2025 (Estimated)ZURAZura Bio-$69.24M-$0.70N/AN/AN/AN/A-37.36%-29.81%8/12/2025 (Estimated)Latest PASG, ZURA, ELUT, and VTGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/10/2025Q4 2025VTGNVistagen Therapeutics-$0.53N/AN/AN/A$0.18 millionN/A5/13/2025Q1 2025PASGPassage Bio-$0.24-$0.25-$0.01-$0.25N/AN/A5/8/2025Q1 2025ELUTElutia-$0.20-$0.21-$0.01-$0.21$6.65 million$6.03 million5/8/2025Q1 2025ZURAZura Bio-$0.17-$0.19-$0.02-$0.19N/AN/A3/25/2025Q4 2024ZURAZura Bio-$0.17-$0.08+$0.09-$0.08N/A$0.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthELUTElutiaN/AN/AN/AN/AN/APASGPassage BioN/AN/AN/AN/AN/AVTGNVistagen TherapeuticsN/AN/AN/AN/AN/AZURAZura BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioELUTElutiaN/A0.940.85PASGPassage BioN/A5.155.15VTGNVistagen TherapeuticsN/A9.359.35ZURAZura BioN/A10.3610.36Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipELUTElutia74.03%PASGPassage Bio53.48%VTGNVistagen Therapeutics78.39%ZURAZura Bio61.14%Insider OwnershipCompanyInsider OwnershipELUTElutia27.60%PASGPassage Bio5.00%VTGNVistagen Therapeutics1.29%ZURAZura Bio14.23%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableELUTElutia18041.12 million20.46 millionNot OptionablePASGPassage Bio13062.15 million59.11 millionOptionableVTGNVistagen Therapeutics4028.86 million28.49 millionOptionableZURAZura Bio368.38 million50.86 millionOptionablePASG, ZURA, ELUT, and VTGN HeadlinesRecent News About These CompaniesMillennium Management LLC Has $1.75 Million Position in Zura Bio Limited (NASDAQ:ZURA)June 3, 2025 | marketbeat.comZura Bio Limited (NASDAQ:ZURA) Given Average Recommendation of "Buy" by BrokeragesMay 26, 2025 | marketbeat.comZura Bio shareholders approve board nominees and auditorMay 24, 2025 | investing.comHC Wainwright Issues Positive Estimate for Zura Bio EarningsMay 23, 2025 | marketbeat.comQ1 Earnings Estimate for Zura Bio Issued By HC WainwrightMay 22, 2025 | marketbeat.comZura Bio commences Phase II trial of tibulizumab for hidradenitis suppurativaMay 21, 2025 | msn.comZura Bio Launches Global Phase 2 TibuSHIELD Study to Evaluate Tibulizumab in Adults with Hidradenitis SuppurativaMay 20, 2025 | businesswire.comZura Bio Reports First Quarter 2025 Financial Results and Recent Corporate UpdatesMay 9, 2025 | standard-journal.comAfter losing 56% in the past year, Zura Bio Limited (NASDAQ:ZURA) institutional owners must be relieved by the recent gainApril 24, 2025 | finance.yahoo.comZura Bio price target lowered to $3 from $5 at H.C. WainwrightApril 4, 2025 | markets.businessinsider.comZura Bio (ZURA) Gets a Buy from GuggenheimMarch 31, 2025 | markets.businessinsider.comHopeful Week For Insiders Who Bought US$1.01m Of Zura Bio StockMarch 26, 2025 | finance.yahoo.comZura Bio Limited: 2024 Financial Results and Strategic ProgressMarch 26, 2025 | tipranks.comZura Bio Reports Full Year 2024 Financial Results and Recent Corporate UpdatesMarch 25, 2025 | businesswire.comZura Bio to Present at the Leerink Partners Global Healthcare ConferenceFebruary 24, 2025 | businesswire.comZURA stock touches 52-week low at $1.44 amid market shiftsFebruary 11, 2025 | msn.comDown -35.58% in 4 Weeks, Here's Why You Should You Buy the Dip in Zura Bio Limited (ZURA)January 24, 2025 | zacks.comWe Think Zura Bio (NASDAQ:ZURA) Can Afford To Drive Business GrowthJanuary 22, 2025 | finance.yahoo.comZura Bio Highlights Strategic Goals and Clinical AdvancesJanuary 13, 2025 | tipranks.comZura Bio initiates Phase II systemic sclerosis treatment trialDecember 25, 2024 | msn.comZura Bio Limited (NASDAQ:ZURA) Director Sells $2,734,458.09 in StockNovember 28, 2024 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePASG, ZURA, ELUT, and VTGN Company DescriptionsElutia NASDAQ:ELUT$1.92 +0.11 (+5.77%) As of 06/6/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators. The company also develops CanGarooRM, a combination of the CanGaroo envelope with antibiotics, to reduce the risk of infection after surgical implantation of an electronic device. In addition, it provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material to repair or reconstruct the peripheral vasculature. Further, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction surgeries following mastectomy. It serves hospitals and healthcare facilities through its direct sales force, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.Passage Bio NASDAQ:PASG$0.42 -0.03 (-6.04%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$0.44 +0.02 (+5.25%) As of 06/6/2025 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.Vistagen Therapeutics NASDAQ:VTGN$2.36 -0.01 (-0.42%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$2.39 +0.03 (+1.44%) As of 06/6/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders. The company was founded in 1998 and is headquartered in South San Francisco, California.Zura Bio NASDAQ:ZURA$1.26 +0.11 (+9.57%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$1.25 -0.01 (-0.79%) As of 06/6/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/02 - 06/06 This Banking Giant Just Got a $90 Price Target Upgrade Broadcom Slides on Solid Earnings, AI Outlook Still Strong The Market’s Silent Warning: What Bonds and Gold Reveal Intel's Dual Gamble: AI Innovation Now, Foundry Fortunes Later? MongoDB Affirms Outlook and Accelerates Stock Price Reversal Five Below Pops on Strong Earnings, But Rally May Stall Are NVIDIA's Ethernet Wins Signs of Hope or Horror for Arista? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
